Ashwagandha under fire: A critical scientific analysis of regulatory decisions

Abstract

Ashwagandha (Withania somnifera [L.] Dunal) is one of the most renowned Ayurvedic medicinal plants, extensively used in traditional Indian medicine systems such as Ayurveda, Siddha, Unani, and Sowa Rigpa for millennia. Its medicinal uses of the root are documented in ancient texts such as the Charaka samhita, Sushruta samhita, and various Nighantus. Recognized globally, Ashwagandha is included in numerous pharmacopoeias, including the Ayurvedic Pharmacopoeia of India (API), British Pharmacopoeia, and United States Pharmacopoeia. Despite its extensive use and documented benefits, Ashwagandha faced scrutiny in Denmark. The Danish Veterinary and Food Administration banned Ashwagandha based on a 2020 report by the Technical University of Denmark (DTU). This report has been criticized for its technical, scientific, and ethical flaws, including reliance on unverified sources and omission of significant data from authoritative compendiums such as the API. Notably, the report’s references often included studies that did not adhere to established standards for Ashwagandha extracts. Furthermore, the alleged abortifacient properties cited in the Danish report are not supported by extensive reviews of traditional texts and modern scientific literature, which indicates the safety of Ashwagandha when used appropriately. This article aims to provide a comprehensive evaluation of the Danish report, emphasizing the necessity of adhering to rigorous scientific standards and accurately representing historical and contemporary data on Ashwagandha.